Heron Therapeutics (HRTX) reported $40.59 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 0.5%. EPS of -$0.02 for the same period compares to $0.02 a year ago.The reported revenue represents no surprise over the Zacks Consensus Estimate of $0 million. With the consensus EPS estimate being -$0.03, the EPS surprise was +33.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

Heron Therapeutics (NasdaqCM:HRTX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsCraig Collard - CEOIra Duarte - EVP and CFOKevin Warner - SVP, Medical Affairs, Strategy, and EngagementMark Hensley - COOMelissa Jarel - Executive Director of LegalConference Call ParticipantsBrandon Folkes - Senior Research AnalystCarl Byrnes - Senior Research AnalystSerge Belanger - Senior AnalystOperatorGood day. Thank you for standing by. Welcome to the Heron Therapeutics Q4 2025 conference call. ...

127,127,127 Heron Therapeutics, Inc. Q4 and Full Year 2025 Earnings Call February 26, 2026 26,68,148 84,184,72 0,125,195 75,40,108 1 Forward-looking Statements and Non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, business and commercializa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 Financial Guidance for 2026 CARY, N.C., February 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron's Acute Care franc ...

Core Insights - Heron Therapeutics reported a 65% year-over-year net revenue growth in its Acute Care franchise, achieving $154.9 million in net revenue for 2025 and providing guidance for 2026 net revenue between $173 million and $183 million, with adjusted EBITDA expected to be between $10 million and $20 million [1][3]. Financial Performance - The Acute Care franchise experienced a revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025 compared to 2024, indicating strong commercial acceleration [4]. - Total net revenue for 2025 was $154.9 million, up from $144.3 million in 2024, reflecting a 7.4% increase [9]. - For Q4 2025, total net revenue was $40.6 million, slightly down from $40.8 million in Q4 2024, marking a 0.5% decrease [10]. Product Updates - ZYNRELEF, a key product, received a permanent product-specific J-Code (J0668) from CMS, effective October 1, 2025, which streamlines reimbursement processes [7]. - The transition to the Vial Access Needle for ZYNRELEF has been completed, enhancing product handling and sterility in hospitals and surgical centers [7]. - APONVIE, another significant product, was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its clinical importance [7]. Market Position and Strategy - The CEO emphasized that the company is entering 2026 with strong momentum, driven by strategic decisions that have unlocked the potential of its assets, particularly ZYNRELEF [2]. - The company is focused on expanding demand signals and improving reimbursement clarity, positioning itself for continued market share gains and revenue growth in 2026 and beyond [2]. Oncology Franchise - The Oncology franchise generated over $105 million in net revenue for 2025, despite facing complex market dynamics [8].

Core Viewpoint - Heron Therapeutics (HRTX) has experienced a decline of over 10% year-to-date, despite an initial rally triggered by preliminary Q4'25 numbers earlier in January [1] Group 1: Company Performance - The company was previously rated a hold, with the analyst noting that HRTX had performed well in its operations [1] Group 2: Market Context - The focus of the analysis includes trading around significant events such as trial results and NDA/BLA approvals, indicating a strategic approach to biotech stock trading [1]

Group 1 - Heron Therapeutics, Inc. will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights [1] - Participants can access the conference call via a registration link for dial-in details and are encouraged to join fifteen minutes early to avoid delays [2] - An archive of the teleconference and webcast will be available on Heron's website for 60 days following the call [2] Group 2 - Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve medical care for patients [3] - The company utilizes advanced science, patented technologies, and an innovative approach to drug discovery and development to create a portfolio of products aimed at enhancing the standard-of-care for acute care and oncology patients [3]

Core Insights - The company reported strong growth in Q4 2025, particularly in its Acute Care franchise, with notable contributions from ZYNRELEF and APONVIE [1] - Overall revenue for Q4 was approximately $40.5 million, with a total net revenue of about $154.9 million for FY25 [1] Financial Performance - Q4 net revenue: approximately $40.5 million for the three months ended December 31 [1] - ZYNRELEF net revenue: approximately $12.5 million for Q4 [1] - APONVIE net revenue: approximately $3.8 million for Q4 [1] - CINVANTI net revenue: approximately $22.9 million for Q4 [1] - SUSTOL net revenue: approximately $1.3 million for Q4 [1] - FY25 total net revenue: approximately $154.9 million [1] - ZYNRELEF experienced the largest quarter-over-quarter revenue increase within the portfolio in Q4 [1]

Core Insights - Heron Therapeutics, Inc. reported preliminary, unaudited net revenue for Q4 and full-year 2025, indicating growth driven by its Acute Care franchise products, ZYNRELEF and APONVIE [1][2] Financial Performance - The company achieved net revenue of approximately $40.5 million for Q4 2025, with ZYNRELEF contributing approximately $12.5 million, APONVIE approximately $3.8 million, CINVANTI approximately $22.9 million, and SUSTOL approximately $1.3 million [7] - For the full year 2025, net revenue reached approximately $154.9 million, with ZYNRELEF showing a quarter-over-quarter revenue increase of about 35% compared to Q3 2025 [7] Product Information - ZYNRELEF is the first extended-release dual-acting local anesthetic approved for postoperative pain management, demonstrating significant efficacy in reducing pain and opioid use post-surgery [3] - APONVIE is a neurokinin 1 receptor antagonist for the prevention of postoperative nausea and vomiting, approved by the FDA in September 2022 and commercially available since March 2023 [5] - CINVANTI is indicated for the prevention of chemotherapy-induced nausea and vomiting, utilizing an IV formulation of aprepitant [8] Company Overview - Heron Therapeutics focuses on developing and commercializing therapeutic innovations aimed at improving patient care, leveraging advanced science and patented technologies [11]